Clinical Trial Detail

NCT ID NCT02433626
Title Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Critical Outcome Technologies Inc.
Indications

head and neck squamous cell carcinoma

pancreatic cancer

lung cancer

fallopian tube cancer

peritoneum cancer

colorectal cancer

ovarian cancer

cervical cancer

Advanced Solid Tumor

endometrial cancer

Therapies

COTI-2

Cisplatin + COTI-2

Age Groups: senior adult

No variant requirements are available.